2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6160 Reporting of race, ethnicity and social determinants of health in ASCO multiple myeloma guidelines

Karla Machlab, MD, Sarah Bahreinian2, Mohab Husien3, John Koussiouris, MD, MSc4, Varsha Nigi Vadassery5, Samuel Sipos6, Lisa Hicks, MD, MSc7
1 University of Toronto, Toronto, Ontario, Canada
2 University of Ottawa, Ottawa, Ontario, Canada
3 St. Michael's Hospital, Toronto, Canada
4 University of Toronto, Toronto, Ontario, Canada
5 Royal College of Surgeons in Ireland - Bahrain, Al Sayh Muharraq Governorate, Bahrain
6 St. Michael's Hospital, Toronto, Canada
7 St. Michael's Hospital, Toronto, Canada

Introduction:

Race, ethnicity and other social determinants of health (SDOH) influence clinical outcomes yet are underreported in randomized control trials (RCTs) (Orkin et al., 2021). To “encourage fairness, equity, consistency and clarity”, and acknowledging that race and ethnicity are social constructs, the JAMA Network published updated guidance in 2021 on the collection and reporting of race and ethnicity in clinical research (Flanagin et al., 2021).

Inclusion of non-White participants, and reporting of race/ethnicity is particularly consequential in multiple myeloma (MM), where significant racial disparities persist. Black patients have more than double the incidence of myeloma compared to White patients and continue to experience inferior clinical outcomes despite treatment advances (Wei et al., 2023). Contributing factors include underrepresentation in clinical trials, socioeconomic determinants, and systemic barriers to healthcare access. Recently, ASCO published evidence-based MM treatment guidelines, informed by data from 161 RCTs. Our study aimed to evaluate the extent to which these trials reported data on race, ethnicity and SDOH, and the representation of minority patients in the trials informing the guideline.

Methods:

A standardized data extraction tool was developed to collect information on the reporting of race, ethnicity and SDOH in the 177 publications of the 161 unique RCTs that informed the ASCO guidelines. Outcomes included if race/ethnicity was reported in the methods section and/or results section, and if so, how participant race/ethnicity was assessed. Additionally, we assessed whether the following SDOH were reported: education, socioeconomic status, employment, housing, and health insurance. We also assessed whether race/ethnicity or SDOH-based subgroup analyses were conducted and whether their implications were discussed. Where reported, the proportion of racial minorities participating in the trial was extracted. Each study was independently reviewed by two reviewers, and data were extracted using the standardized tool. Any discrepancies between the reviewers were identified and resolved by a third reviewer. Data was analyzed with descriptive statistics.

Results:

Across 177 articles, reporting of race, ethnicity and SDOH was infrequent. Overall, 70 (39.5%) studies reported race/ethnicity in the results and 12 (6.8%) in the methods or methods-referenced supplement. Only 2 studies stated any reason for assessing race/ethnicity and 12 discussed its implications. No trial reported other SDOH domains.

Reporting of race/ethnicity improved over time, from 11.5% of trials published in 2005-2009, 17.1%  in 2010-2014, 52.1% in 2015-2019 and 52.2% in 2020-2024.

Among the trials reporting participation by race or ethnicity, enrolment was predominantly White in every time-period: median 82.8% White (IQR 74.9-89.5%), with 59.7% of trials ≥80% White, and none below 56%.

Conclusion:

Multiple myeloma disproportionately impacts Black patients. However, a minority (only 39.5%) of trials informing recent evidence-based guidelines on myeloma included information of on race/ethnicity of participants. There was a trend to increasing reporting of race/ethnicity over time. Other SDOH were not reported at all. Among trials reporting on race/ethnicity, non-White participants were under-represented. Although clinical trials are increasingly reporting on race and ethnicity, underreporting remains an important issue and SDOH is not reported, contributing to healthcare inequity and the generalizability of trial results.

Karla Machlab, MD: No relevant conflicts of interest to declare.